Combined company targets mitochondrial biology and body composition as longevity biotech edges into mainstream markets
Pulmatrix and Eos SENOLYTIX have announced a definitive merger agreement that will see the combined entity, which will operate under the Eos name and trade under the ticker EOSX, positioning itself squarely within the emerging field of gerotherapeutics – therapies designed to target the underlying biology of aging rather than its downstream manifestations. The transaction, supported by $19 million in concurrent private financing, is intended to advance Eos’s lead candidate, PTC-2105, toward clinical development in sarcopenia and related conditions.
The deal reflects a broader shift in how aging is being approached within biopharma; not as an abstract risk factor, but as a tractable, targetable driver of disease. Eos, founded in 2021, has focused its efforts on mitochondrial dysfunction and cellular senescence – two hallmarks increasingly implicated in metabolic decline, frailty and chronic disease. Pulmatrix, for its part, brings public market infrastructure and a clinical development framework, creating a vehicle through which these ideas may begin to translate.
Longevity.Technology: The proposed merger between Pulmatrix and Eos SENOLYTIX reads, at first glance, as a familiar biotech transaction – a pipeline, some capital, a new ticker – yet the subtext is rather more revealing. What is being assembled here is not simply a company, but a category; one that leans into the increasingly confident language of “gerotherapeutics” and, in doing so, signals a shift from aging as a research lens to aging as a primary therapeutic target. The timing is instructive. In the wake of GLP-1’s commercial ascent, the conversation is shifting from the sheer magnitude of weight loss to the biological cost of achieving it. We are moving past the scale’s blunt verdict – “how much?” – to a more forensic set of questions: what kind of tissue was sacrificed, and what was preserved? It is a reframing that drags muscle mass and metabolic resilience from the clinical periphery to the absolute center of the frame. Against this backdrop, Eos’s dual-lever approach—tuning mitochondrial function while clearing the cellular “zombies” of senescence—feels less like a niche intervention and more like a necessary evolution. This isn’t about chasing a single endpoint; it’s about systemic recalibration. Whether this platform can leap the formidable chasm between mouse models and human outcomes is the multi-million dollar question, but the direction of travel is unmistakable. Longevity is no longer content to sit adjacent to mainstream medicine; it is beginning to structure itself within it – commercially, clinically and conceptually.
A platform built around mitochondrial biology
At the center of the combined company’s strategy is MitoXcel, Eos’s proprietary platform for developing so-called geropeptides – molecules designed to modulate mitochondrial function and selectively eliminate senescent cells. Its lead asset, PTC-2105, is intended to address sarcopenia and sarcopenic obesity, conditions characterized by declining muscle mass and function that affect tens of millions globally and currently lack approved therapies.
The mechanics here are unapologetically upstream. By tuning mitochondrial membrane potential and nudging dysfunctional cells toward a programmed exit, PTC-2105 bypasses the surface-level symptoms of metabolic disease to intervene at a foundational level. This is biology that sits beneath traditional diagnostic categories, addressing the cellular wear-and-tear that anchors multiple pathologies at once. In preclinical settings, this translated into more than just shifting numbers on a scale; it produced a genuine physiological pivot: shedding fat mass while simultaneously bolstering lean muscle and physical performance. It is a set of outcomes that mirrors the core mandate of longevity medicine – not just the absence of disease, but the restoration of function.
Two mechanisms. One target.
The GLP-1 inflection point
The strategic context is difficult to ignore. GLP-1 receptor agonists have redefined obesity treatment, yet their limitations are increasingly part of the conversation. Alongside reductions in visceral fat, these therapies are associated with losses in lean mass – estimated at between 25% and 40% of total weight loss – as well as issues such as gastrointestinal side effects and weight regain following discontinuation.
Eos is positioning PTC-2105 not as a competitor to the GLP-1 hegemony, but as its necessary sophisticated counterpart. Preclinical data suggests a more discerning biological outcome: the ability to strip away fat mass while augmenting lean mass. Whether deployed as a standalone or as a corrective to the “muscle tax” often paid on semaglutide, the distinction is fundamental. We are moving away from the blunt mechanism of appetite suppression toward the elegant logic of tissue-level remodeling. It is a shift in focus from the sheer quantity of weight lost to the biological quality of what remains.
As Dr Kevin Slawin, Founder and CEO of Eos, put it: “We believe the focus in obesity will shift from percentage body weight loss to the composition of that weight loss… including effects on visceral fat and lean mass, which are important predictors of overall health and long-term survival.”
From obesity to aging biology
The company’s ambitions extend beyond metabolic disease. By targeting mitochondrial dysfunction and senescent cells, the MitoXcel platform is positioned as a broader gerotherapeutic approach with potential applications across cognitive decline, neurodegeneration and other age-related conditions.
This breadth reflects a particular view of aging biology – one in which disparate diseases share common upstream drivers. Address those drivers, the logic goes, and multiple downstream pathologies may be modulated in parallel. It is a compelling thesis, though one that remains to be tested in human trials.
Pulmatrix CEO Peter Ludlum framed the opportunity in similarly expansive terms, describing Eos’s approach as “developing a differentiated platform addressing diseases with significant unmet medical need.”
“Eos’s innovative approach to targeting mitochondrial dysfunction and senescent cells represents a compelling scientific and strategic opportunity that builds on the recent approval of FORZINITY (elamipretide), the first FDA-approved mitochondrial-targeted therapeutic,” he added.
Capital, structure and timing
The $19 million capital injection serves as the bridge from concept to clinic, earmarked for IND-enabling studies and the first-in-human stage 1b/2a trials that will test the MitoXcel hypothesis. That the resulting ownership structure leans so heavily toward Eos stakeholders is telling; it is a clear nod to the fact that while Pulmatrix provides the vessel, the biological intellectual property remains the primary engine of value.
More broadly, the transaction follows a familiar biotech playbook – marrying early-stage innovation to the liquidity and visibility of public markets – yet the nomenclature has changed. Geroscience is shedding its academic robes and venture-backed insularity. It is beginning to speak the pragmatic, high-stakes language of clinical milestones, regulatory clearance, and total addressable markets. We are witnessing the professionalization of longevity; a field once defined by its “what ifs” is now being built on the “how tos.”
A field taking shape
What we are seeing is not a solitary clinical breakthrough, but the convergence of several powerful, intersecting currents: the steady maturation of longevity science, the necessary evolution of metabolic medicine, and a growing, collective recognition that aging is not a background condition, but a legitimate therapeutic target. These narratives are no longer running in parallel; they are colliding. And in that collision, the definition of what it means to treat a patient – and what it means to succeed – is being fundamentally rewritten.
Still early. Still uncertain.
Yet the contours are becoming visible. Not in declarations, but in deals – transactions that quietly translate theory into structure, and structure into something that begins to resemble a market.
Photographs courtesy of Eos SENOLYTIX
